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Heme oxygenase-1 (HO-1, encoded 
by HMOX1) through degradation of 
pro-oxidant heme into carbon mon-
oxide (CO), ferrous ions (Fe2+) and 
biliverdin, exhibits cytoprotective, 
anti-apoptotic and anti-inflammato-
ry properties. All of these potential-
ly beneficial functions of HO-1 may 
play an important role in tumors’ 
development and progression. More-
over, HO-1 is very often upregulated 
in tumors in comparison to healthy 
tissues, and its expression is further 
induced upon chemo-, radio- and 
photodynamic therapy, what results 
in decreased effectiveness of the 
treatment. Consequently, HO-1 can be 
proposed as a  therapeutic target for 
anticancer treatment in many types of 
tumors. Nonetheless, possibilities of 
specific inhibition of HO-1 are strongly 
limited. Metalloporphyrins are widely 
used in in vitro studies, however, they 
are unselective and may exert seri-
ous side effects including an increase 
in HMOX1 mRNA level. On the oth-
er hand, detailed information about 
pharmacokinetics and biodistribution 
of imidazole-dioxolane derivatives, 
other potential inhibitors, is lacking. 
The genetic inhibition of HO-1 by RNA 
interference (RNAi) or CRISPR/Cas9 
approaches provides the possibility 
to specifically target HO-1; however, 
the potential therapeutic application 
of those methods are distant at best.
In summary, HO-1 inhibition might 
be the valuable anticancer approach, 
however, the ideal strategy for HO-1 
targeting requires further studies.
Key words: HO-1 inhibitors, siRNA, 
CRISPR/Cas9, anticancer strategy, tu-
morigenesis.
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Biological functions of HO-1 – an overview 
Heme, an organic cofactor composed of iron and organic part called pro-
toporphyrin IX, serves as a prosthetic group of many proteins. Hence, it facil-
itates a wide variety of processes like electron transport (cytochrome P450 
family), enzyme catalysis (e.g. peroxidase, catalase, cyclooxygenase, nitric 
oxide synthase) and reversible binding of gases (hemoglobin, myoglobin, 
guanylate cyclase). Furthermore, it is involved in regulation of protein syn-
thesis and cells differentiation [1]. From the other hand, free heme released 
from intracellular hemeproteins causes cellular and tissue damage. Toxic 
and pro-oxidant properties of heme are the consequences of iron-depen-
dent reactive oxygen species (ROS) generation, lipids peroxidation and dis-
ruption of cellular membranes. As the result, an excessive level of circulating 
heme leads to several pathologies [2]. 
To overcome deleterious properties of heme, cellular machinery is 
equipped with heme oxygenases (HO), a microsomal enzymes which are re-
sponsible for the first, rate-limiting step in heme degradation pathway. The 
enzyme cleaves heme into three biological active products: carbon monox-
ide (CO), ferrous ions (Fe2+) and biliverdin, which is subsequently converted 
into antioxidant bilirubin by biliverdin reductase. Molecular oxygen, cyto-
chrome P450 reductase, and NADPH are required for the complete reaction 
[3]. So far, three isoforms of HO have been described – HO-1, HO-2 and 
HO-3; however, the latter is rather the pseudogene originated from HO-2 
transcript and was identified only in rats [4]. Although both HO-1 (encoded 
by HMOX1 gene) and HO-2 (encoded by HMOX2 gene) catalyze the same 
reaction in heme degradation pathway and share approximately 40% ho-
mology, they differ in various aspects, including the kinetics of catalyzed 
reaction and the level of their expression in selected tissues. Finally, what is 
the most important, HO-2 is a constitutive isoform, whereas HO-1 – induc-
ible. According to that, HO-1 is strongly upregulated in response to a wide 
spectrum of stimuli such as its substrate heme, proinflammatory cytokines, 
ROS, nitric oxide (NO), metalloporphyrins, heavy metals, prostaglandins, UV 
irradiation and many others. At the molecular level, expression of HO-1 is 
mainly activated by the transcription factor Nrf2 (nuclear factor erythroid 
2-related factor-2). Certain stimuli cause the release of Nrf2 from its inhib-
itor, Keap-1 (Kelch-like associating protein 1) and this lead to translocation 
of Nrf2 to the nucleus where it binds to antioxidant response element (ARE) 
located within the promoter of theHMOX1 gene. Moreover, several other 
transcription factors (e.g. AP-1, STAT and NF-κB) may be responsible for 
the induction of HO-1 expression in stressful conditions, such as oxidative 
stress (reviewed in: [5, 6]).
Thus, except degradation of pro-oxidant heme, HO-1 exerts much broad-
er and pleiotropic functions mediated by the end products of its activity. 
Carbon monoxide (CO) is a gasotransmitter which among several functions 
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activates soluble guanylate cyclase (sGC) and cause va-
sodilation and inhibition of platelet aggregation. Through 
modulation of MAPK (mitogen-activated protein kinases) 
pathways, it exerts anti-inflammatory functions: decreas-
es leukocyte adhesion, inhibits pro- and increases anti-in-
flammatory cytokines. Additionally, CO possess anti-prolif-
erative and anti-apoptotic properties leading to protection 
from tissue injury, however these functions are tissue-spe-
cific (reviewed in [6]). Moreover, its positive effect on an-
giogenic activity of endothelial and vascular smooth cells 
has been described [7, 8]. Ferrous ions increase the expres-
sion of ferritin, which is responsible for iron sequestration, 
hence it prevents toxicity caused by production of hydrox-
yl radicals. Additionally, Fe2+ ions induce iron transporter 
(Fe-ATPase) responsible for iron efflux. Finally, biliverdin 
and bilirubin possess anti-oxidant and anti-inflammato-
ry properties by scavenging ROS, decreasing membrane 
lipids peroxidation, and inhibiting complement cascade 
(reviewed in: [6]). 
Emergent role of heme oxygenase-1 (HO-1)  
in tumor biology
Unfortunately, all of the above mentioned cytoprotec-
tive actions of HO-1 and its by-products can be harmful, es-
pecially when translated into pathophysiological process-
es like tumorigenesis. Expression of HO-1 is significantly 
elevated in tumors, in comparison to healthy tissues, in-
cluding pancreatic cancer, melanoma, renal cell carcinoma 
and others (reviewed in [9]). Noteworthy, expression of 
HO-1 can be further enhanced by anticancer therapies (in-
cluding radio-, chemo- and photodynamic therapy) what 
often results in decreased effectiveness of the treatment 
[10–12] (Fig. 1).
It has to be stressed that the increased expression of 
HO-1 is found predominantly, but not only, in tumor cells 
(Fig. 2). Already in 1999, Nishie et al. have demonstrated 
the association of HO-1 with infiltrating macrophages and 
vascular densities in human gliomas [13]. HO-1 expres-
sion in the stromal macrophages has been also shown in 
the other cancer tissues. HO-1 expressed in FAP+/CD45+ 
inflammatory macrophages with a M2 phenotype was 
demonstrated to play a crucial role in immune suppres-
sion [14]. Moreover, HO-1-specific regulatory CD8+ T cells 
were detected both in peripheral blood of cancer patients 
and among tumor-infiltrating lymphocytes in situ of can-
cer patients [15]. HO-1-specific Treg cells were able to sup-
press immune response against cancer cells and efficiently 
inhibited T cell responses, including cytokine release, pro-
liferation and cytotoxicity [15]. Interestingly, in melanoma, 
HO-1 was almost exclusively expressed in macrophages 
and the negligible expression was found in the tumor cells 
and other stromal cell types [16].
One important aspect of HO-1 effect on tumor biology 
might be related to its cellular localization. Generally, HO-1 
localizes mainly in the cytoplasm where it is associated 
with endoplasmic reticulum (ER), caveoli or mitochondria 
[17]; however, it was also found in the nucleus [18]. Such 
nuclear localization was observed in the lung [19], prostate 
[20] and head and neck cancer [21] and it correlated with 
poor prognosis and progression of the disease. Although 
the exact mechanism of such localization is not known 
yet, it was suggested that in response to stressful condi-
tions, HO-1 can be cleaved and translocated to the nucleus 
where it mediates upregulation of genes involved in an-
ti-oxidant response and cytoprotection [18] (Fig. 2).
The exact role of HO-1 in tumor biology is multifaceted 
(Fig. 1). Although HO-1 is mostly shown to exert pro-tum-
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Fig. 2. Expression of HO-1 in tumors. Elevated level of HO-1 has been 
found in many types of tumors, both in cancer cells themselves and 
in immune cells such as macrophages and T regulatory cells, em-
phasizing its role in modulation of tumor microenvironment and 
evasion of the immune response against cancer. Interestingly, al-
though HO-1 localizes mainly in cytoplasm, also its truncated, nucle-
ar form has been linked with poor prognosis and progression of the 
disease in certain types of tumors; however, this mechanism is still 
not fully understood
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Fig. 1. HO-1 as a target for anticancer therapy. HO-1 expression in 
tumor tissues is increased as a consequence of oncogenic transfor-
mation, modified by HO-1 promoter polymorphism, and further up-
regulated in response to anticancer therapies. Generally, HO-1 exerts 
pro-tumorigenic effects through an increase in proliferation, surviv-
al, and angiogenesis. However, also the opposite, inhibitory effect on 
the progression of tumors have been reported in some tumor types
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origenic properties by affecting cancer cells proliferation, 
survival and metastasis, also opposite effects have been 
described. Such anti-tumorigenic action of HO-1 favoring 
cancer development or/and survival was demonstrated in 
case of breast, prostate, pancreatic cancer and non-small 
cell lung carcinoma. This reflects complex and dual role of 
HO-1 in different types on tumors.
HO-1 can directly enhance proliferation of cancer cells 
what was shown in vitro and was further confirmed in vivo 
in the case of pancreatic cancer [10, 22], melanoma [23], 
and rhabdomyosarcoma [39]. Interestingly, Li et al. [24] 
have demonstrated that HO-1 plays an important role in 
lung cancer carcinogenesis induced by tobacco-specific ni-
trosamine. An elevated level of HO-1 was associated with 
increased proliferation of cancer cells through upregula-
tion of p21, an inhibitor of apoptosis protein 2 (c-IAP2) and 
B-cell lymphoma-2 (Bcl-2) with a concomitant decrease in 
Bad protein. This, in turn, promoted the growth of cancer 
cells and prevented their death. 
Also increased production of growth factors, such as 
epidermal growth factor (EGF) or elevated level of some 
mitogenic receptors like fibroblast growth factor recep-
tor-1 (FGFR1) correlated with the accelerated proliferation 
of melanoma cancer cells [23]. However, also the opposite, 
anti-proliferative effect of HO-1 was observed in breast 
cancer [25] and prostate cancer [26] where pharmacologi-
cal inhibition of HO-1 resulted in an augmented prolifera-
tion of cancer cells.
Cytoprotective and anti-apoptotic properties of HO-1 
in tumors are well known. In general, overexpression of 
HO-1 correlates with increased survival of cancer cells and 
their resistance to potentially toxic, anticancer drugs or 
therapies [12, 27]. There are several possible mechanisms 
through which HO-1 may affect apoptosis of cancer cells. For 
instance, in gastric cancer, an elevated level of HO-1 con-
tributed to decrease in caspase-3, the crucial mediator of 
apoptosis [28]. It was also demonstrated that HO-1 can di-
rectly inhibit apoptosis via activation of Akt (protein kinase 
B) pathway and this, in turn, can lead to increased ratio of 
antiapoptotic Bcl-2 (B-cell lymphoma-2) to proapoptotic Bax 
(Bcl-2-associated X protein) proteins in colon cancer cell line 
[29]. Furthermore, genetic inhibition of HO-1 in breast can-
cer cell lines resulted in augmented doxorubicin-induced 
apoptosis via downregulation of antiapoptotic proteins [30]. 
However, some contradictory results showed that overex-
pression of HO-1 did not protect breast cancer cells from 
chemopreventive agents-induced apoptosis [31].
Interestingly, the role of autophagy in cancer biology 
is being widely studied and discussed nowadays, mostly 
due to its paradoxical role both in promoting and inhib-
iting cancer development and progression [32]. The link 
between HO-1 and autophagy has been reported in renal 
cancer, as overexpression of HO-1 induced by rapamycin 
and sorafenib treatment was reported to enhance survival 
of cancer cells by induction of anti-apoptotic B-cell lym-
phoma-extra large (Bcl-xL) protein and inhibition of au-
tophagy [33]. On the other hand, upregulation of HO-1 in 
breast cancer cell lines exposed to doxorubicin treatment 
was accompanied with increased, cytoprotective autopha-
gy via Scr-STAT3 signaling pathway [34].
HO-1 can directly support angiogenesis, the process de-
fined as the formation of new blood vessels from preexist-
ing vasculature, extremely important for tumor expansion 
and invasiveness. HO-1 can upregulate the expression or 
activity of proangiogenic factors like, among others, vas-
cular endothelial growth factor (VEGF) (reviewed in: [35]) 
and stromal cell-derived factor-1 (SDF-1) [7]. Such proan-
giogenic effect of HO-1 was clearly demonstrated in glio-
ma [13], pancreatic cancer [22], Kaposi sarcoma [36], mela-
noma [23], urothelial carcinoma [37], prostate cancer [38], 
and rhabdomyosarcoma [39]. Additionally, pharmacologi-
cal inhibition of HO-1 resulted in suppressed angiogenesis 
and reduced VEGF level in mouse lung cancer in vivo [40]. 
Of importance, HO-1 overexpression may also contrib-
ute to enhanced metastasis as it was reported in the case 
of melanoma [23], pancreatic cancer [22] and squamous 
cell carcinoma [41]. Additionally, an elevated level of HO-1 
in patients suffering from non-small cell lung cancer (NS-
CLC) was correlated with poor prognosis and enhanced 
metastasis occurrence [42]. However, in our hands, HO-1 
overexpression in NSCLC NCI-H292 cells, caused not only 
decrease in their proliferation, migration and angiogenic 
potential, but also inhibition of tumors growth in vivo [43]. 
We observed that a high level of HO-1 in NSCLC cells cor-
related with a low expression of miR-378, the known on-
comir and angiomir. Furthermore, treatment with CORM-2, 
CO-releasing molecule, decreased the expression of miR-
378 and consequently decreased expression of angiogenic 
mediators [43].
Another possible mechanism of HO-1 action might be 
connected with the effect on cell differentiation. Our initial 
experiments performed on murine C2C12 myoblasts sug-
gested that HO-1 overexpression increases proliferation rate 
and the resistance to oxidative stress, however, it negatively 
regulates the differentiation of myoblasts to skeletal mus-
cles [44]. Blockage of myotubes formation was independent 
of antioxidant properties of HO-1 but involved the inhibition 
of cEBPδ-dependent expression of myoD and regulation of 
specific microRNAs, namely myomirs (miR-1, miR-133a, miR-
133b, and miR-206), responsible for myoblast differentia-
tion. Downregulation of myomirs as well as other muscle 
regulatory factors including a master regulatory switch for 
myogenesis, MyoD and myogenin, by HO-1 overexpression 
was mimicked by CO-releasing molecule [44]. 
Based on such observations we performed experi-
ments on rhabdomyosarcoma (RMS) tumor cell lines and 
primary RMS specimens. We observed the correlation of 
HO-1 expression with cancer invasiveness – much higher 
expression of HO-1 was detected in alveolar, more aggres-
sive RMS (aRMS) than embryonal subtype. High expres-
sion of HO-1 was correlated with the decreased expression 
of miR-206, necessary for myoblasts differentiation [39]. 
In vivo, after subcutaneous injection of aRMA cell line and 
chemical inhibitor of HO activity application (SnPPIX), the 
growth of tumor was potently inhibited. What is more, the 
analysis of tumor vasculature indicated that HO-1 inhibi-
tion exerted a potent anti-angiogenic effect. Lower num-
ber of CD-31 positive cells indicating decreased tumor vas-
cularization was observed in SnPPIX-treated animals and 
those data were confirmed by in vivo ultrasonography im-
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aging. In accordance with those results, the comparison of 
primary RMS specimens showed that in HO-1 overexpress-
ing tumors were better vascularized. Further studies are 
necessary to fully describe the role of HO-1 in disturbed 
cell differentiation in other tumor types and to understand 
the molecular mechanism of the observed effects.
Synthetic lethality of HMOX1 and FH genes
A unique evidence suggesting the relevance of HO-1 in 
tumor biology is its implication in hereditary leiomyoma-
tosis and renal cell cancer (HLRCC) disease, a condition 
caused by inherited, autosomal dominant mutation in 
fumarate hydratase (FH) gene [45]. Mutation of FH, a tri-
carboxylic acid cycle enzyme, results in a permanently in-
creased level of fumarate, which is proposed to act as an 
oncometabolite through a various mechanism [46].
Interestingly, Adam et al. demonstrated that HMOX1 ex-
pression was significantly upregulated both in FH-deficient 
cells and in a mouse model of FH-deficiency [47]. Moreover, 
silencing of HMOX1 in FH-deficient cell lines resulted in their 
synthetic lethality [48]. This term refers to the situation in 
which simultaneous defect in two genes causes cell death, 
whereas at the same time separate dysfunction or muta-
tion of each gene does not affect cells viability [49]. In silico 
study which was subsequently confirmed experimentally 
pointed out the importance of heme biosynthesis and deg-
radation pathways in FH-deficient cells linking glutamine 
uptake (as a source of carbon required for heme biosynthe-
sis) with bilirubin excretion. Indeed, 18 out of 24 genes pre-
dicted as synthetically lethal with FH, were associated with 
heme metabolism pathways. Importantly, genetic or phar-
macological inhibition of HMOX1 significantly diminished 
survival of FH-deficient cells [48]. Also in our hands, genetic 
inhibition of HMOX1 in UOK262 cell line, which lacks FH ac-
tivity, decreased cells viability, proliferation, and clonogenic 
potential (unpublished data). Hence, HMOX1 can serve as 
a potential therapeutic target also for patients suffering 
from HLRCC disease.
Association between HO-1 gene polymorphism 
and cancer
Noteworthy, genetic variation like polymorphism of 
HO-1 promoter and its association with cancer suscepti-
bility was a subject of several studies. The human HMOX1 
gene promoter in its 5′-flanking region contains a different 
number of GT microsatellite repeats, (GT)n, ranging from 
11 to 40 [50]. Bimodal frequency distribution of (GT)n re-
peat lengths was observed in many populations studied, 
with the main alleles being 23 and 30 repeats (reviewed 
in: [6]). This genetic variability was shown to influence 
the response to exogenous stimuli, e.g. we showed that 
endothelial cells expressing the S allele (short, GT≤ 23) 
have high basal HO-1 expression and strong induction in 
response to hydrogen peroxide (H2O2), lipopolysaccharide 
(LPS), prostaglandin J2(PGJ2) and cobalt protoporphyrin 
(CoPPIX) [51]. 
It has been demonstrated that shorter (GT)n repeats 
within the HMOX1 promoter results in higher transcription-
al activity and this, in turn, attributes to the increased risk 
and poor prognosis of pancreatic cancer [52] and gastric 
cancer [53]. Patients with a shorter version of the promotor 
are more susceptible to the development of pancreatic can-
cer and recurrence of the disease [52]. This data correlate 
with other results indicating higher HO-1 expression in pan-
creatic tumors than in healthy tissue [10] and accelerated 
tumor growth, angiogenesis and metastatic potential of 
pancreatic cancer when HO-1 is overexpressed [22]. 
On the other hand, the long (GT)n repeats in HMOX1 
gene promoter was reported to correlate with a higher 
risk of breast cancer [54], esophageal squamous cell car-
cinoma [55] and laryngeal squamous cell carcinoma [56]. 
More complicated, other studies showed no correlation 
between HMOX1 polymorphism and the risk of lung squa-
mous cell carcinoma [57] and sporadic colorectal cancer 
[58], indicating that the final outcome may depend on 
several factors including the type of the tumor, subject 
ethnicity, and many others. In accordance with all those 
various results, the meta-analysis of 10 studies involving 
2,367 cases and 2,870 controls found no correlation be-
tween the length of (GT)n sequence and overall cancer 
risk although for some specific tumor types the associa-
tion was reported [59].
HO-1 as a therapeutic target in cancer – 
different ways of HO-1 inhibition
As described above, inhibition of HO-1 may be con-
sidered as a mode for anticancer treatment. However, it 
cannot be rather effective as a single therapy, but most 
likely as an additional therapeutic strategy that could in-
crease the sensitivity of the cancer cells to chemotherapy 
or radiotherapy. Inhibition of HO-1 can be achieved either 
through genetic tools or pharmacological agents (Fig. 3).
Genetic inhibition of HO-1 expression  
(RNA interference, CRISPR/Cas9)
RNA interference (RNAi) enables selective inhibition of 
desired genes on post-transcriptional, mRNA level. Small 
interfering RNA (siRNA) and short hairpin RNA (shRNA) are 
the most commonly used forms of RNAi whose action re-
sults in gene silencing either through cleavage of targeted 
mRNA, chromatin remodeling or blockage of protein syn-
thesis. The usefulness of RNAi approach in studying gene 
functions has been widely reported in many areas of re-
search including carcinogenesis (reviewed in: [60]).
Of importance, a substantial number of studies evaluat-
ing the role of HO-1 inhibition in cancer has been conduct-
ed using siRNA or shRNA sequences specifically targeting 
HO-1 transcript. Application of HO-1 siRNA in vitro result-
ed in beneficial increase in apoptosis of lung cancer cells 
[61], colon carcinoma cells [29], leukemic cells [62-64] and 
esophageal squamous carcinoma cells [65]. Furthermore, 
increased sensitivity to chemotherapeutics of pancreatic 
cancer cells [10], myeloid leukemia cells [66] and some 
other types of cancer cells was also reported (reviewed 
in: [27]). In contrast, a comprehensive study performed on 
prostate cancer cell line PC3 revealed rather pro-tumori-
genic effect of HO-1 downregulation by siRNA, related to 
changes in cell-cell contact [67].
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In vivo application of HO-1 siRNA/shRNA sequences 
or cancer cells modified by RNAi was also demonstrated. 
Direct, intraperitoneal injection of HO-1 siRNA resulted in 
the diminished growth of tumors in an orthotopic model 
of hepatocellular carcinoma [68]. Moreover, subcutaneous 
injection of human colon cancer cell line resistant to 5-flu-
orouracil (5-FU), transduced with shRNA against HO-1, sig-
nificantly reduced tumor size and markedly increased the 
sensitivity of nude mice to 5-FU treatment [69].
Since its discovery, RNAi provided invaluable insight into 
molecular pathways and potential targets involved in tu-
mor development and progression. Nonetheless, therapeu-
tic application of RNAi remains limited by several factors 
related to variable efficiency and off-target effects, delivery 
of genetic material into specific tumor sites, questionable 
stability and possible triggering of immune response [70].
Most recently, novel and extremely powerful genetic 
tool – CRISPR (clustered regularly interspaced short palin-
dromic repeat) – Cas9 (CRISPR-associated nuclease 9) sys-
tem, adopted from bacteria defense mechanism against 
viral infection, has opened new possibilities to specifically 
knock-out any desired gene at the genomic level. In brief, 
the Cas9 nuclease is guided to specific genomic locus by 
single guide RNA sequence (sgRNA) where it induces dou-
ble strand breaks (DSB) subsequently repaired by DNA 
repair mechanisms, such as non-homologous end joining 
DNA repair pathway (NHEJ). As the repair mechanism is an 
error-prone, insertions and deletions occur, what, in con-
sequence, may lead to gene knock-out through changes in 
mRNA reading frame and the introduction of the prema-
ture stop codon. CRISPR/Cas9 system, due to its specificity, 
efficiency, and simplicity, starts being a method of choice 
to study gene functions, also in tumor biology, where its 
therapeutic application was suggested (reviewed in: [71]). 
In our recent studies done on a model cell line, 293T, we 
confirmed the high effectiveness of CRISPR/Cas9 to spe-
cifically and efficiently target HO-1 (unpublished data). Al-
though there are commercially available tools to generate 
HO-1 knock-out, there is a lack of studies evaluating the 
role of HO-1 in cancer using CRISPR/Cas9 technology, what, 
most probably, is just a matter of time. Of importance, ex-
cept undeniable advantages of CRISPR/Cas9 technology, 
its drawbacks, namely possible off-target effects, delivery 
methods and others (reviewed in: [72]), have to be also 
taken into account when considering the experimental or 
therapeutic application of CRISPR/Cas9 system. 
Pharmacological inhibition of HO-1 activity
Another approach is based on the inhibition of HO ac-
tivity using pharmacological agents, namely: well-known 
and characterized metalloporphyrins like zinc protopor-
phyrin (ZnPPIX), tin protoporphyrin (SnPPIX) or chromium 
protoporphyrin (CrPPIX) and imidazole-based compounds 
(Fig. 3).
Metalloporphyrins (MPs) are heme analogues com-
posed of protoporphyrin IX in which iron atom is exchanged 
by another component. The structure of these molecules 
Fig. 3. Tools for HO-1 inhibition. Both genetic and pharmacological tools for HO-1 inhibition are available; however, all exert some disadvan-
tages. Still more basic studies are necessary to identify the new, “ideal” specific inhibitors of HO-1 activity and/or to broaden our knowledge 
about CRISPR/Cas9 technology or siRNA targeting HO-1
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allows them to bind in the heme binding pocket of HO and 
instead of activation of the enzyme, they competitively 
inhibit its activity [73]. MPs have a much higher binding 
affinity than heme to HO isoforms and are not oxidatively 
degraded as they have no oxygen-binding capacity [74]. 
Majority of MPs have been shown to inhibit HO activity 
in vitro and in vivo, but protoporphyrins with nickel (Ni), 
copper (Cu), and magnesium (Mg) as central atoms do not 
affect HO activity. Oppositely, CoPPIX acts as a stimulant of 
HO activity and it is strong inducer of HO-1 expression This 
effect results from the robust induction of HO-1 gene ex-
pression through the repression of Bach1 and upregulation 
of the Nrf2 protein [75]. Another study showed also the 
involvement of FOXO1 transcription factor in CoPPIX–me-
diated regulation of HO-1 expression [76].
Numerous experimental studies confirmed the useful-
ness of MPs in decreasing HO activity. For instance, treat-
ment of cultured melanoma tumor with SnPPIX markedly 
enhanced the efficiency of photodynamic therapy [77] and 
attenuated Kaposi sarcoma growth in vivo [78]. Moreover, 
ZnPPIX significantly increased photodynamic therapy-me-
diated cytotoxicity towards colon carcinoma and ovarian 
carcinoma cells [12]. Inhibition of HO-1 by ZnPPIX increased 
the sensitivity of nasopharyngeal carcinoma cells to radio-
therapy [79] and intensified effectiveness of cisplatin in 
liver cancer both in vitro and in vivo [80]. 
Unfortunately, due to the long list of disadvantages 
(Fig. 3, Table 1) the experimental and medical application 
of MPs is strongly limited. One of the major drawback is 
the photoreactivity of most of the MPs which may cause 
phototoxicity leading to tissue and even organ damage 
[74, 81]. Moreover, they are highly lipophilic, thus insol-
uble in aqueous solutions. It was partially overcome by 
conjugation of the polyethylene-glycol [82] or amphiphil-
ic styrene-maleic acid copolymer [83] to ZnPPIX, which 
resulted in the creation of water-soluble agents with po-
tent HO inhibitory effect (PEG-ZnPPIX and SMA-ZnPPIX, 
respectively). Importantly, the anti-tumor effectiveness 
of these compounds was confirmed both in vitro and in 
vivo, without any apparent side effects [84, 85]. Neverthe-
less, several disadvantages are hard to overcome by any 
modification. One of them is a lack of selectivity. MPs not 
only inhibit the activity of both isoenzymes of HO [86] but 
because of the similarity of structure to heme, most of 
them also affect other heme-dependent enzymes like ni-
tric oxide synthases (NOS), soluble guanylyl cyclase (sGC) 
or cytochromes P450 (CYPs) [87, 88]. Paradoxically, they 
also induce HO-1 on mRNA and protein level [9, 89, 90, 
91]. These wide-ranging actions cause potential concerns 
in the interpretation of effects ascribed to MPs. Moreover, 
many undesired, independent of HO inhibition events 
were reported as the results of ZnPPIX and SnPPIX action. 
Interestingly, Wang et al. observed that cytotoxic effect of 
ZnPPIX on human ovarian and prostate cancer cell lines 
was altered neither by overexpression nor by knockout of 
HO-1, suggesting HO-1 independent effect of this inhibitor 
[92]. Similarly, in human colon [93], hepatoma and chronic 
myelogenous leukemia cell lines, as well as in BCL1 (B-cell 
leukemia/lymphoma 1)-tumor bearing mice [94], decrease 
in cancer cells proliferation and growth of tumors in vivo 
after ZnPPIX treatment was a direct consequence of cyclin 
D1 suppression and independent of HO-1 inhibition.
It has to be emphasized that HO inhibitors may act not 
only on tumor cells directly, but may also influence other 
cell types, including inflammatory cells (Fig. 4). Arnold et 
al. [14] have investigated the role of HO-1 expressing FAP+/
CD45+ macrophages associated with immunosuppression 
in tumorigenesis. Importantly they showed, that inhibi-
tion of HO-1 by Sn mesoporphyrin (SnMP) caused the im-
mune-dependent arrest of tumor growth that was similar 
to the FAP+/CD45+ cells depletion.
Also T cell can play a role in immune suppression. A few 
years ago it was shown not only that HO-1 is highly ex-
pressed in a specific subpopulation of Treg cells but also 
that this subpopulation is accumulating in the glioma tu-
mor during the progression of the disease and most likely 
play an immunosuppressive role [95]. Moreover, another 
group showed that overexpression of HO-1 in Treg cells is 
associated with better survival in hypoxia, typical for tu-
mors, and inhibition of HO-1 using SnPP is able to revoke 
this effect, suggesting a protective role of the enzyme. Im-
portantly, in in vivo experiment, SnPP treatment reduced 
the number of Treg cells in brain tumor microenvironment, 
what increased survival of the tumor-bearing mice [96].
Interestingly, systemic application of ZnPPIX in vivo into 
neuroblastoma-bearing mice as well as injection of neu-
roblastoma cell line NXS2 pre-treated with ZnPPIX into 
syngeneic mouse model significantly improved CD4+ and 
CD8+ T-effector cells functions and maturation of den-
dritic cells (DCs) via increased production of IL-10 [97]. In 
a mouse model of breast cancer, inhibition of HO-1 by ZnP-
PIX was associated with polarization of tumor-associated 
macrophages (TAM) towards M1-like phenotype (CD11b+ 
Fig. 4. The effect of HO-1 inhibition on tumor development and sen-
sitivity to anticancer therapies. In cancer cells, the inhibition of HO-1 
using metalloporphyrins (MPs), imidazole-based compounds, RNAi 
or CRISPR/Cas9 system can affect tumor development in various 
manner, both directly and indirectly. Directly, it may lead to increased 
apoptosis, impaired proliferation and invasiveness and reduction of 
the tumor size. The indirect effect is associated with increased sensi-
tivity to anticancer treatments, like photo-, chemo- and radio- thera-
py by stimulation of the immune system and enhanced angiogenesis
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F4/80low CD206-) with anti-tumorigenic effectiveness 
[98]. Interestingly, recent study done by the group of Di 
Biase et al. showed that fasting-mimicking diet combined 
with chemotherapy triggers immune response against 
breast and melanoma cancer via an increase in lymphoid 
progenitor cells and CD8+ cytotoxic T lymphocytes. This, 
at least partially, was associated with downregulation of 
HO-1, also confirmed by the application of ZnPPIX [99].
Although all described so far effects of metalloporphy-
rins on anti-tumor immune response have been ascribed to 
specific HO-1 inhibition, one cannot exclude their unspecif-
ic mode of action. Indeed, Metz et al. have demonstrated 
that ZnPPIX specifically inhibits indoleamine 2,3-dioxygen-
ase (IDO) enzyme, which is thought to favor immune escape 
in many types of tumors. The application of ZnPPIX and, as 
the results, inhibition of IDO in vivo in melanoma-bearing 
mice, resulted in anti-tumor effectiveness related to T-cell 
function, rather than HO-1 inhibition [100].
In order to enhance the progress in understanding 
the role of HO-1 in different pathological conditions, new, 
non-porphyrin-based class of HO inhibitors, without some 
drawbacks of MPs, were synthesized and evaluated. First 
was azalanstat which is an imidazole-dioxolane compound 
[101]. Based on its structure, and by changing the substit-
uents, many new, preferentially more selective for HO-1 
isoform inhibitors were designed [102, 103]. Noteworthy, 
some of the compounds exhibit low or even no inhibitory 
activity on NOS, CYPs, and sGC, what is one of the major 
advantages over MPs [104] (Fig. 3, Table 1).
For the last couple of years, a lot of new inhibitors were 
developed, starting with QC-308 [105] or QC-13 [106]. All of 
these inhibitors differ in their potency to inhibit HO activi-
ty, their stability, eventual cytotoxicity and specificity [88]. 
One of the things that combine them all is the proposed 
mechanism of action. Imidazole-dioxolane derivatives 
act as non-competitive agents by binding to the distal 
side of heme and eventually causing displacement of the 
critical for catalysis (heme oxidation) water ligand [107]. 
Moreover, developed inhibitors are soluble and stable in 
physiological solutions [88]. Potent antitumor effect of 
imidazole-based HO-1 inhibitors was confirmed recently 
in prostate and breast cancer cell lines, however, the con-
centration of used compounds was quite high [108]. Ad-
ditionally, promising antitumor effects were obtained for 
compound referred as OB-24. Inhibition of HO-1 activity in 
hormone-refractory prostate cancer resulted in decreased 
proliferation, viability and invasiveness of cancer cell in 
vitro. Furthermore, treatment of tumor-bearing mice with 
OB-24 significantly reduced growth and metastasis of tu-
mors in vivo and this effect was potentiated together with 
the treatment with Taxol [109].
Nevertheless, we still lack detailed data on the phar-
macokinetics, biodistribution and safety of this new class 
of inhibitors. For the last few years, our group was also 
involved in the study concerning searching for the new HO 
activity inhibitors. Until this day, we obtained some prom-
ising results which still require further validation.
Summary 
As summarized in this review, inhibition of HO-1 can be 
considered as a potential anticancer strategy in various 
cancer types through several possible mechanisms (Fig. 4). 
Genetic inhibition of HMOX1 by shRNA approach, although 
has shown promising, anticancer effectiveness is still far 
from the therapeutic application. On the other hand, 
pharmacological inhibition of HO activity was shown to 
be effective, but due to the several limitations of known 
metalloporphyrin inhibitors, the advantage of this strate-
Table 1. Comparison of HO inhibitors 
Metalloporphyrins Imidazole-based compounds
Examples • Protoporphyrins: ZnPP, SnPP, CrPP • QC-1 (azalanstat)
• Mesoporphyrins: ZnMP, SnMP, CrMP • QC-13
• Deuteroporphyrins: ZnDP, SnDP, CrDP • QC-308
• Modifications: PEG-ZnPP, SMA-ZnPP  
Major features • Competitive inhibitors • Non-competitive inhibitors
• “Classical” protoporphyrins are water insoluble, • Water soluble
•  “Modified” protoporphyrins: PEG-ZnPP and SMA-ZnPP  
are water soluble and are claimed to be more available
• Some exert selectivity against HO isoforms
• Potent inhibitors of HO activity 
• Well-studied  
Adverse effects • Not selective towards HO isoforms • Not studied widely in vitro and in vivo
• Inducers of HO-1 expression • Not tested in clinical studies
• Modulators of NOS, sGC, and CYPs 
• Photosensitizers 
• Limited bioavailability 
• Inhibitors of IDO, cyclin D1 and WNT/β-catenin (ZnPP)
CrDP – chromium deuteroporphyrin; CrMP – chromium mesoporphyrin; CrPP – chromium protoporphyrin, CYPs – Cytochromes P450; IDO – indoleamine 
2,3-dioxygenase; NOS – nitric oxide synthase; sGC – soluble guanyl cyclase; SnDP – tin deuteroporphyrin; SnMP – tin mesoporphyrin; SnPP – tin protoporphyrin, 
ZnDP – zinc deuteroporphyrin; ZnMP – zinc mesoporphyrin; ZnPP; ZnPP – zinc protoporphyrin; SMA-ZnPP – styrene maleic acid ZnPP; PEG-ZnPP – polyethylene 
glycol ZnPP
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gy is also doubtful. A better alternative may provide nov-
el, small inhibitors of HO activity; however, a substantial 
number of studies is still needed to drive any conclusions 
about their anticancer effectiveness and potential thera-
peutic application. 
This work was supported by the grant from the Na-
tional Centre for Research and Development (PBS2/
B7/15/2014) and from the National Science Centre 
(2016/21/B/NZ1/00293). Faculty of Biochemistry, Biophys-
ics and Biotechnology of Jagiellonian University is a part-
ner of the Leading National Research Center (KNOW) sup-
ported by the Ministry of Science and Higher Education. 
Figures were produced using Servier Medical Art (http://
www.servier.com).
References
1. Ponka P. Cell biology of heme. Am J Med Sci 1999; 318: 241-56.
2. Kumar S, Bandyopadhyay U. Free heme toxicity and its detoxifi-
cation systems in human. Toxicol Lett 2005; 157: 175-88.
3. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion 
of heme to bilirubin by microsomal heme oxygenase. Proc Natl 
Acad Sci USA 1968; 61: 748-55.
4. Hayashi S, Omata Y, Sakamoto H, Higashimoto Y, Hara T, Sagara 
Y, Noguchi M. Characterization of rat heme oxygenase-3 gene. 
Implication of processed pseudogenes derived from heme oxy-
genase-2 gene. Gene 2004; 336: 241-50.
5. Loboda A, Damulewicz M, Pyza E, Jozkowicz A, Dulak J. Role of 
Nrf2/HO-1 system in development, oxidative stress response and 
diseases: an evolutionarily conserved mechanism. Cell Mol Life 
Sci 2016; 73: 3221-47.
6. Loboda A, Jazwa A, Grochot-Przeczek A, Rutkowski AJ, Cisowski 
J, Agarwal A, Jozkowicz A, Dulak J. Heme oxygenase-1 and the 
vascular bed: from molecular mechanisms to therapeutic oppor-
tunities. Antioxid Redox Signal 2008; 10: 1767-812.
7. Deshane J, Chen S, Caballero S, et al. Stromal cell-derived factor 
1 promotes angiogenesis via a heme oxygenase 1-dependent 
mechanism. J Exp Med 2007; 204: 605-18.
8. Dulak J, Jozkowicz A, Foresti R, et al. Heme oxygenase activity 
modulates vascular endothelial growth factor synthesis in vas-
cular smooth muscle cells. Antioxid Redox Signal 2002; 4: 229-
40.
9. Loboda A, Jozkowicz A, Dulak J. HO-1/CO system in tumor growth, 
angiogenesis and metabolism – Targeting HO-1 as an anti-tumor 
therapy. Vascul Pharmacol 2015; 74: 11-22.
10. Berberat PO, Dambrauskas Z, Gulbinas A, et al. Inhibition of heme 
oxygenase-1 increases responsiveness of pancreatic cancer cells 
to anticancer treatment. Clin Cancer Res 2005; 11: 3790-8.
11. Kongpetch S, Kukongviriyapan V, Prawan A, Senggunprai L, Ku-
kongviriyapan U, Buranrat B. Crucial role of heme oxygenase-1 on 
the sensitivity of cholangiocarcinoma cells to chemotherapeutic 
agents. PLoS One 2012; 7: e34994.
12. Nowis D, Legat M, Grzela T, et al. Heme oxygenase-1 protects tu-
mor cells against photodynamic therapy-mediated cytotoxicity. 
Oncogene 2006; 25: 3365-74.
13. Nishie A, Ono M, Shono T, et al. Macrophage infiltration and 
heme oxygenase-1 expression correlate with angiogenesis in hu-
man gliomas. Clin Cancer Res 1999; 5: 1107-13.
14. Arnold JN, Magiera L, Kraman M, Fearon DT. Tumoral immune 
suppression by macrophages expressing fibroblast activation pro-
tein-alpha and heme oxygenase-1. Cancer Immunol Res 2014; 2: 
121-6.
15. Andersen MH, Sorensen RB, Brimnes MK, Svane IM, Becker JC, 
thor Straten P. Identification of heme oxygenase-1-specific reg-
ulatory CD8+ T cells in cancer patients. J Clin Invest 2009; 119: 
2245-56.
16. Torisu-Itakura H, Furue M, Kuwano M, Ono M. Co-expression 
of thymidine phosphorylase and heme oxygenase-1 in macro-
phages in human malignant vertical growth melanomas. Jpn J 
Cancer Res 2000; 91: 906-10.
17. Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monox-
ide: from basic science to therapeutic applications. Physiol Rev 
2006; 86: 583-650.
18. Lin Q, Weis S, Yang G, et al. Heme oxygenase-1 protein localizes 
to the nucleus and activates transcription factors important in 
oxidative stress. J Biol Chem 2007; 282: 20621-33.
19. Hsu FF, Yeh CT, Sun YJ, Chiang MT, Lan WM, Li FA, Lee WH, Chau LY. 
Signal peptide peptidase-mediated nuclear localization of heme 
oxygenase-1 promotes cancer cell proliferation and invasion in-
dependent of its enzymatic activity. Oncogene 2015; 34: 2410-1.
20. Sacca P, Meiss R, Casas G, Mazza O, Calvo JC, Navone N, Vazquez 
E. Nuclear translocation of haeme oxygenase-1 is associated to 
prostate cancer. Br J Cancer 2007; 97: 1683-9.
21. Gandini NA, Fermento ME, Salomon DG, et al. Nuclear localiza-
tion of heme oxygenase-1 is associated with tumor progression 
of head and neck squamous cell carcinomas. Exp Mol Pathol 
2012; 93: 237-45.
22. Sunamura M, Duda DG, Ghattas MH, et al. Heme oxygenase-1 
accelerates tumor angiogenesis of human pancreatic cancer. An-
giogenesis 2003; 6: 15-24.
23. Was H, Cichon T, Smolarczyk R, et al. Overexpression of heme 
oxygenase-1 in murine melanoma: increased proliferation and 
viability of tumor cells, decreased survival of mice. Am J Pathol 
2006; 169: 2181-98.
24. Li MY, Yip J, Hsin MK, Mok TS, Wu Y, Underwood MJ, Chen GG. 
Haem oxygenase-1 plays a central role in NNK-mediated lung 
carcinogenesis. Eur Respir J 2008; 32: 911-23.
25. Hill M, Pereira V, Chauveau C, et al. Heme oxygenase-1 inhibits 
rat and human breast cancer cell proliferation: mutual cross inhi-
bition with indoleamine 2,3-dioxygenase. FASEB J 2005; 19: 1957-
68.
26. Gueron G, De Siervi A, Ferrando M, et al. Critical role of endog-
enous heme oxygenase 1 as a tuner of the invasive potential of 
prostate cancer cells. Mol Cancer Res, 2009; 7: 1745-55.
27. Na HK, Surh YJ. Oncogenic potential of Nrf2 and its principal tar-
get protein heme oxygenase-1. Free Radic Biol Med, 2014; 67: 
353-65.
28. Liu ZM, Chen GG, Ng EK, Leung WK, Sung JJ, Chung SC. Upregula-
tion of heme oxygenase-1 and p21 confers resistance to apopto-
sis in human gastric cancer cells. Oncogene 2004; 23: 503-13.
29. Busserolles J, Megias J, Terencio MC, Alcaraz MJ. Heme oxygenase-1 
inhibits apoptosis in Caco-2 cells via activation of Akt pathway. Int 
J Biochem Cell Biol 2006; 38: 1510-7.
30. Zhu XF, Li W, Ma JY, et al. Knockdown of heme oxygenase-1 pro-
motes apoptosis and autophagy and enhances the cytotoxicity 
of doxorubicin in breast cancer cells. Oncol Lett 2015; 10: 2974-
80.
31. Andreadi CK, Howells LM, Atherfold PA, Manson MM. Involve-
ment of Nrf2, p38, B-Raf, and nuclear factor-kappaB, but not 
phosphatidylinositol 3-kinase, in induction of hemeoxygenase-1 
by dietary polyphenols. Mol Pharmacol 2006; 69: 1033-40.
32. White E. The role for autophagy in cancer. J Clin Invest 2015; 125: 
42-6.
33. Banerjee P, Basu A, Wegiel B, et al. Heme oxygenase-1 promotes 
survival of renal cancer cells through modulation of apoptosis- 
and autophagy-regulating molecules. J Biol Chem 2012; 287: 
32113-23.
34. Tan Q, Wang H, Hu Y, et al. Src/STAT3-dependent heme oxygen-
ase-1 induction mediates chemoresistance of breast cancer cells 
to doxorubicin by promoting autophagy. Cancer Sci 2015; 106: 
1023-32.
35. Loboda A, Jazwa A, Wegiel B, Jozkowicz A, Dulak J. Heme oxy-
genase-1-dependent and -independent regulation of angiogen-
ic genes expression: effect of cobalt protoporphyrin and cobalt 
chloride on VEGF and IL-8 synthesis in human microvascular 
endothelial cells. Cell Mol Biol (Noisy-le-grand) 2005; 51: 347-55.
36. Mcallister SC, Hansen SG, Ruhl RA, Raggo CM, DeFilippis VR, 
Greenspan D, Früh K, Moses AV. Kaposi sarcoma-associated her-
31Heme oxygenase inhibition in cancers: possible tools and targets
pesvirus (KSHV) induces heme oxygenase-1 expression and ac-
tivity in KSHV-infected endothelial cells. Blood 2004; 103: 3465-
73.
37. Miyake M, Fujimoto K, Anai S, et al. Heme oxygenase-1 promotes 
angiogenesis in urothelial carcinoma of the urinary bladder. On-
col Rep 2011; 25: 653-60.
38. Birrane G, Li H, Yang S, Tachado SD, Seng S. Cigarette smoke in-
duces nuclear translocation of heme oxygenase 1 (HO-1) in pros-
tate cancer cells: nuclear HO-1 promotes vascular endothelial 
growth factor secretion. Int J Oncol 2013; 42: 1919-28.
39. Ciesla M, Marona P, Kozakowska M, et al. Heme Oxygenase-1 
Controls an HDAC4-miR-206 Pathway of Oxidative Stress in 
Rhabdomyosarcoma. Cancer Res 2016; 76: 5707-18.
40. Hirai K, Sasahira T, Ohmori H, Fujii K, Kuniyasu H. Inhibition of 
heme oxygenase-1 by zinc protoporphyrin IX reduces tumor 
growth of LL/2 lung cancer in C57BL mice. Int J Cancer 2007; 120: 
500-5.
41. Lee SS, Yang SF, Tsai CH, Chou MC, Chou MY, Chang YC. Upregula-
tion of heme oxygenase-1 expression in areca-quid-chewing-as-
sociated oral squamous cell carcinoma. J Formos Med Assoc 
2008; 107: 355-63.
42. Tsai JR, Wang HM, Liu PL, et al. High expression of heme oxy-
genase-1 is associated with tumor invasiveness and poor clinical 
outcome in non-small cell lung cancer patients. Cell Oncol (Dor-
dr) 2012; 35: 461-71.
43. Skrzypek K, Tertil M, Golda S, et al. Interplay between heme ox-
ygenase-1 and miR-378 affects non-small cell lung carcinoma 
growth, vascularization, and metastasis. Antioxid Redox Signal 
2013; 19: 644-60.
44. Kozakowska M, Ciesla M, Stefanska A, et al. Heme oxygenase-1 
inhibits myoblast differentiation by targeting myomirs. Antioxid 
Redox Signal 2012; 16: 113-27.
45. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH 
predispose to dominantly inherited uterine fibroids, skin leiomy-
omata and papillary renal cell cancer. Nat Genet 2002; 30: 406-
10.
46. Yang M, Soga T, Pollard PJ, Adam J. The emerging role of fumarate 
as an oncometabolite. Front Oncol 2012; 2: 85.
47. Adam J, Hatipoglu E, O’Flaherty L, et al. Renal cyst formation in 
Fh1-deficient mice is independent of the Hif/Phd pathway: roles 
for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 
2011; 20: 524-37.
48. Frezza C, Zheng L, Folger O, et al. Haem oxygenase is synthetically 
lethal with the tumour suppressor fumarate hydratase. Nature 
2011; 477: 225-8.
49. Nijman SM. Synthetic lethality: general principles, utility and detec-
tion using genetic screens in human cells. FEBS Lett 2011; 585: 1-6.
50. Exner M, Minar E, Wagner O, Schillinger M. The role of heme oxy-
genase-1 promoter polymorphisms in human disease. Free Radic 
Biol Med 2004; 37: 1097-104.
51. Taha H, Skrzypek K, Guevara I, et al. Role of heme oxygenase-1 
in human endothelial cells: lesson from the promoter allelic vari-
ants. Arterioscler Thromb Vasc Biol 2010; 30: 1634-41.
52. Vashist YK, Uzungolu G, Kutup A, et al. Heme oxygenase-1 germ 
line GTn promoter polymorphism is an independent prognostica-
tor of tumor recurrence and survival in pancreatic cancer. J Surg 
Oncol 2011; 104: 305-11.
53. Sawa T, Mounawar M, Tatemichi M, Gilibert I, Katoh T, Ohshima 
H. Increased risk of gastric cancer in Japanese subjects is asso-
ciated with microsatellite polymorphisms in the heme oxygen-
ase-1 and the inducible nitric oxide synthase gene promoters. 
Cancer Lett 2008; 269: 78-84.
54. Hong CC, Ambrosone CB, Ahn J, et al. Genetic variability in 
iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and 
HO-1), iron intake, and risk of postmenopausal breast cancer. 
Cancer Epidemiol Biomarkers Prev 2007; 16: 1784-94.
55. Hu JL, Li ZY, Liu W, Zhang RG, Li GL, Wang T, Ren JH, Wu G. Poly-
morphism in heme oxygenase-1 (HO-1) promoter and alcohol are 
related to the risk of esophageal squamous cell carcinoma on 
Chinese males. Neoplasma 2010; 57: 86-92.
56. Tang D, Tang WJ, Shi XL, Li WP, Zhou H, Lu LM, Tao L. Association 
of the microsatellite (GT)n repeat polymorphisms of the HO-1 
gene promoter and corresponding serum levels with the risk of 
laryngeal squamous cell carcinoma. Acta Otolaryngol 2016; 136: 
806-11.
57. Kikuchi A, Yamaya M, Suzuki S, et al. Association of susceptibility 
to the development of lung adenocarcinoma with the heme ox-
ygenase-1 gene promoter polymorphism. Hum Genet 2005; 116: 
354-60.
58. Jiraskova A, Novotny J, Novotny L, et al. Association of serum bili-
rubin and promoter variations in HMOX1 and UGT1A1 genes with 
sporadic colorectal cancer. Int J Cancer 2012; 131: 1549-55.
59. Zhang L, Song FF, Huang YB, et al. Association between the (GT)n 
polymorphism of the HO-1 gene promoter region and cancer risk: 
a meta-analysis. Asian Pac J Cancer Prev 2014; 15: 4617-22.
60. Abdelrahim M, Safe S, Baker C, et al. RNAi and cancer: Implica-
tions and applications. J RNAi Gene Silencing, 2006; 2: 136-45.
61. Kim HR, Kim S, Kim EJ, et al. Suppression of Nrf2-driven heme 
oxygenase-1 enhances the chemosensitivity of lung cancer A549 
cells toward cisplatin. Lung Cancer 2008; 60: 47-56.
62. Mayerhofer M, Gleixner KV, Mayerhofer J, et al. Targeting of heat 
shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic 
cells in chronic myeloid leukemia: a novel approach to overcome 
resistance against imatinib. Blood 2008; 111: 2200-10.
63. Rushworth SA, Macewan DJ. HO-1 underlies resistance of AML 
cells to TNF-induced apoptosis. Blood 2008; 111: 3793-801.
64. Wei S, Wang Y, Chai Q, Fang Q, Zhang Y, Wang J. Potential cross-
talk of Ca2+-ROS-dependent mechanism involved in apoptosis of 
Kasumi-1 cells mediated by heme oxygenase-1 small interfering 
RNA. Int J Oncol 2014; 45: 2373-84.
65. Ren QG, Yang SL, Hu JL, Li PD, Chen YS, Wang QS. Evaluation of 
HO-1 expression, cellular ROS production, cellular proliferation 
and cellular apoptosis in human esophageal squamous cell car-
cinoma tumors and cell lines. Oncol Rep 2016; 35: 2270-6.
66. Zhe N, Wang J, Chen S, Lin X, Chai Q, Zhang Y, Zhao J, Fang Q. 
Heme oxygenase-1 plays a crucial role in chemoresistance in 
acute myeloid leukemia. Hematology 2015; 20: 384-91.
67. Paez AV, Pallavicini C, Schuster F, et al. Heme oxygenase-1 in 
the forefront of a multi-molecular network that governs cell-cell 
contacts and filopodia-induced zippering in prostate cancer. Cell 
Death Dis 2016; 7: e2570.
68. Sass G, Leukel P, Schmitz V, et al. Inhibition of heme oxygenase 1 
expression by small interfering RNA decreases orthotopic tumor 
growth in livers of mice. Int J Cancer 2008; 123: 1269-77.
69. Kang KA, Piao MJ, Kim KC, et al. Epigenetic modification of Nrf2 in 
5-fluorouracil-resistant colon cancer cells: involvement of TET-de-
pendent DNA demethylation. Cell Death Dis 2014; 5: e1183.
70. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and 
challenges. Adv Drug Deliv Rev 2007; 59: 75-86.
71. Yi L,Li J, CRISPR-Cas9 therapeutics in cancer: promising strategies 
and present challenges. Biochim Biophys Acta 2016; 1866: 197-
207.
72. Peng R, Lin G,Li J, Potential pitfalls of CRISPR/Cas9-mediated ge-
nome editing. FEBS J 2016; 283: 1218-31.
73. Maines MD. Zinc protoporphyrin is a selective inhibitor of heme 
oxygenase activity in the neonatal rat. Biochim Biophys Acta 
1981; 673: 339-50.
74. Schulz S, Wong RJ, Vreman HJ, Stevenson DK. Metalloporphyrins 
– an update. Front Pharmacol 2012; 3: 68.
75. Shan Y, Lambrecht RW, Donohue SE, Bonkovsky HL. Role of Bach1 
and Nrf2 in up-regulation of the heme oxygenase-1 gene by co-
balt protoporphyrin. FASEB J 2006; 20: 2651-3.
76. Liu X, Cui Y, Li M, Xu H, Zuo J, Fang F, Chang Y. Cobalt protoporphy-
rin induces HO-1 expression mediated partially by FOXO1 and re-
duces mitochondria-derived reactive oxygen species production. 
PLoS One 2013; 8: e80521.
77. Frank J, Lornejad-Schäfer MR, Schöffl H, Flaccus A, Lambert C, 
Biesalski HK. Inhibition of heme oxygenase-1 increases respon-
siveness of melanoma cells to ALA-based photodynamic therapy. 
Int J Oncol 2007; 31: 1539-45.
78. Marinissen MJ, Tanos T, Bolós M, de Sagarra MR, Coso OA, 
Cuadrado A. Inhibition of heme oxygenase-1 interferes with the 
transforming activity of the Kaposi sarcoma herpesvirus-encod-
ed G protein-coupled receptor. J Biol Chem 2006; 281: 11332-46.
32 contemporary oncology
79. Shi L, Fang J. Implication of heme oxygenase-1 in the sensitivity 
of nasopharyngeal carcinomas to radiotherapy. J Exp Clin Cancer 
Res 2008; 27: 13.
80. Liu YS, Li HS, Qi DF, Zhang J, Jiang XC, Shi K, Zhang XJ, Zhang XH. 
Zinc protoporphyrin IX enhances chemotherapeutic response of 
hepatoma cells to cisplatin. World J Gastroenterol 2014; 20: 8572-
82.
81. Vreman HJ, Ekstrand BC, Stevenson DK. Selection of metallopor-
phyrin heme oxygenase inhibitors based on potency and photo-
reactivity. Pediatr Res 1993; 33: 195-200.
82. Sahoo SK, Sawa T, Fang J, Tanaka S, Miyamoto Y, Akaike T, Mae-
da H. Pegylated zinc protoporphyrin: a water-soluble heme oxy-
genase inhibitor with tumor-targeting capacity. Bioconjug Chem 
2002; 13: 1031-8.
83. Iyer AK, Greish K, Seki T, Okazaki S, Fang J, Takeshita K, Maeda H. 
Polymeric micelles of zinc protoporphyrin for tumor targeted de-
livery based on EPR effect and singlet oxygen generation. J Drug 
Target 2007; 15: 496-506.
84. Fang J, Sawa T, Akaike T, Akuta T, Sahoo SK, Khaled G, Hamada A, 
Maeda H. In vivo antitumor activity of pegylated zinc protopor-
phyrin: targeted inhibition of heme oxygenase in solid tumor. 
Cancer Res 2003; 63: 3567-74.
85. Herrmann H, Kneidinger M, Cerny-Reiterer S, et al. The Hsp32 in-
hibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory 
effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells. 
Curr Cancer Drug Targets 2012; 12: 51-63.
86. Wong RJ, Vreman HJ, Schulz S, Kalish FS, Pierce NW, Stevenson 
DK. In vitro inhibition of heme oxygenase isoenzymes by metal-
loporphyrins. J Perinatol 2011; 31 Suppl 1: S35-41.
87. Appleton SD, Chretien ML, Mclaughlin BE, Vreman HJ, Stevenson 
DK, Brien JF, Nakatsu K, Maurice DH, Marks GS. Selective inhibi-
tion of heme oxygenase, without inhibition of nitric oxide syn-
thase or soluble guanylyl cyclase, by metalloporphyrins at low 
concentrations. Drug Metab Dispos 1999; 27: 1214-9.
88. Kinobe RT, Dercho RA, Nakatsu K. Inhibitors of the heme oxygen-
ase – carbon monoxide system: on the doorstep of the clinic? 
Can J Physiol Pharmacol 2008; 86: 577-99.
89. Kwok SC. Zinc Protoporphyrin Upregulates Heme Oxygenase-1 in 
PC-3 Cells via the Stress Response Pathway. Int J Cell Biol 2013; 
2013: 162094.
90. Sardana MK, Kappas A. Dual control mechanism for heme oxy-
genase: tin(IV)-protoporphyrin potently inhibits enzyme activity 
while markedly increasing content of enzyme protein in liver. 
Proc Natl Acad Sci USA 1987; 84: 2464-8.
91. Yang G, Nguyen X, Ou J, Rekulapelli P, Stevenson DK, Dennery 
PA. Unique effects of zinc protoporphyrin on HO-1 induction and 
apoptosis. Blood 2001; 97: 1306-13.
92. Wang S, Avery JE, Hannafon BN, Lind SE, Ding WQ. Zinc protopor-
phyrin suppresses cancer cell viability through a heme oxygen-
ase-1-independent mechanism: the involvement of the Wnt/
beta-catenin signaling pathway. Biochem Pharmacol 2013; 85: 
1611-8.
93. Nowis D, Bugajski M, Winiarska M, et al. Zinc protoporphyrin IX, 
a heme oxygenase-1 inhibitor, demonstrates potent antitumor 
effects but is unable to potentiate antitumor effects of chemo-
therapeutics in mice. BMC Cancer 2008; 8: 197.
94. La P, Fernando AP, Wang Z, Salahudeen A, Yang G, Lin Q, 
Wright CJ, Dennery PA. Zinc protoporphyrin regulates cyclin 
D1 expression independent of heme oxygenase inhibition. 
J Biol Chem 2009; 284: 36302-11.
95. El Andaloussi A, Lesniak MS. CD4+ CD25+ FoxP3+ T-cell infiltra-
tion and heme oxygenase-1 expression correlate with tumor 
grade in human gliomas. J Neurooncol 2007; 83: 145-52.
96. Chauveau C, Remy S, Royer PJ, et al. Heme oxygenase-1 expres-
sion inhibits dendritic cell maturation and proinflammatory func-
tion but conserves IL-10 expression. Blood 2005; 106: 1694-702.
97. Fest S, Soldati R, Christiansen NM, et al. Targeting of heme ox-
ygenase-1 as a novel immune regulator of neuroblastoma. Int 
J Cancer 2016; 138: 2030-42.
98. Deng R, Wang SM, Yin T, et al. Inhibition of tumor growth and al-
teration of associated macrophage cell type by an HO-1 inhibitor 
in breast carcinoma-bearing mice. Oncol Res 2013; 20: 473-82.
99. Di Biase S, Lee C, Brandhorst S, et al. Fasting-Mimicking Diet Re-
duces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity. Can-
cer Cell, 2016; 30: 136-46.
100. Metz R, Duhadaway JB, Rust S, Munn DH, Muller AJ, Mautino M, 
Prendergast GC. Zinc protoporphyrin IX stimulates tumor immu-
nity by disrupting the immunosuppressive enzyme indoleamine 
2,3-dioxygenase. Mol Cancer Ther, 2010; 9: 1864-71.
101. Vlahakis JZ, Kinobe RT, Bowers RJ, Brien JF, Nakatsu K, Szarek WA. 
Synthesis and evaluation of azalanstat analogues as heme oxy-
genase inhibitors. Bioorg Med Chem Lett 2005; 15: 1457-61.
102. Vlahakis JZ, Hum M, Rahman MN, Jia Z, Nakatsu K, Szarek WA. 
Synthesis and evaluation of imidazole-dioxolane compounds as 
selective heme oxygenase inhibitors: effect of substituents at 
the 4-position of the dioxolane ring. Bioorg Med Chem 2009; 17: 
2461-75.
103. Vlahakis JZ, Kinobe RT, Bowers RJ, Brien JF, Nakatsu K, Szarek WA. 
Imidazole-dioxolane compounds as isozyme-selective heme oxy-
genase inhibitors. J Med Chem, 2006; 49: 4437-41.
104. Kinobe RT, Vlahakis JZ, Vreman HJ, Stevenson DK, Brien JF, Szarek 
WA, Nakatsu K. Selectivity of imidazole-dioxolane compounds 
for in vitro inhibition of microsomal haem oxygenase isoforms. 
Br J Pharmacol 2006. 147: 307-15.
105. Rahman MN, Vlahakis JZ, Vukomanovic D, Lee W, Szarek WA, Na-
katsu K, Jia Z. A novel, “double-clamp” binding mode for human 
heme oxygenase-1 inhibition. PLoS One 2012; 7: e29514.
106. Pittala V, Salerno L, Romeo G, Modica MN, Siracusa MA. A focus 
on heme oxygenase-1 (HO-1) inhibitors. Curr Med Chem 2013; 
20: 3711-32.
107. Rahman MN, Vlahakis JZ, Roman G, Vukomanovic D, Szarek WA, 
Nakatsu K, Jia Z. Structural characterization of human heme oxy-
genase-1 in complex with azole-based inhibitors. J Inorg Biochem 
2010; 104: 324-30.
108. Salerno L, Pittala V, Romeo G, et al. Novel imidazole derivatives 
as heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) in-
hibitors and their cytotoxic activity in human-derived cancer cell 
lines. Eur J Med Chem 2015; 96: 162-72.
109. Alaoui-Jamali MA, Bismar TA, Gupta A, et al. A novel experimen-
tal heme oxygenase-1-targeted therapy for hormone-refractory 
prostate cancer. Cancer Res 2009; 69: 8017-24.
Address for correspondence
Agnieszka Łoboda and Józef Dulak 
Department of Medical Biotechnology 
Faculty of Biochemistry, Biophysics and Biotechnology,
Jagiellonian University
Gronostajowa 7
30-387 Krakow, Poland 
e-mail: agnieszka.loboda@uj.edu.pl
e-mail: jozef.dulak@uj.edu.pl
